Imagine a medicine that stays asleep while traveling through the body and only wakes up when it finds a tumor with low oxygen levels. This project uses AI to pick the right patients who will respond best to this 'smart' drug. It's like having a guided missile that only explodes inside the enemy camp, leaving healthy areas untouched.
Many solid tumors are resistant to standard therapies due to hypoxia (low oxygen), and current treatments often lack the precision to target these areas without causing systemic toxicity.
A hypoxia-activated prodrug (CP-506) and two AI-driven biomarkers to identify responding patients. The project has also launched an electronic Case Report Form (eCRF) for clinical data collection.
If you are a drug developer dealing with the high failure rates of chemotherapy—this project developed CP-506 that targets hypoxic tumors representing over 50% of all solid tumors. This allows for more precise treatment and potentially higher efficacy rates.
If you are a diagnostics firm dealing with imprecise patient selection for immunotherapy—this project developed AI-driven biomarkers for tumor hypoxia and Homologous Recombination Defect. This ensures the right patients receive the treatment, improving progression-free survival.
If you are a clinic dealing with the high toxicity of standard cancer treatments—this project developed a hypoxia-activated prodrug that exhibits low toxicity. This improves the quality of life for patients undergoing treatment for resistant cancers.
The project aims to pave the way for a licensing agreement with the potential to exceed €450M.
Based on available project data, specific pricing or cost-per-dose information is not provided; the focus is currently on Phase I-IIa clinical trials.
The project is currently advancing from TRL 5 to TRL 6 through Phase I clinical trials, meaning it is in the clinical validation stage rather than full industrial scale.
Convert Pharmaceuticals holds IP for CP-506 and another hypoxia-activated prodrug that has already been tested in Phase I and II trials.
The trial has already been approved by regulatory authorities in the Netherlands and Belgium.
The project period is from 2024-01-01 to 2025-12-31, focusing on completing Phase I and laying the groundwork for Phase II.
The project is led by a single SME, Convert Pharmaceuticals (Belgium), representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company manages both the drug development and the AI biomarker innovation internally without relying on academic partners for the current phase.
Contact Convert Pharmaceuticals SA in Belgium
Contact us to explore licensing opportunities for CP-506
